Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF ‐mutated melanoma and other advanced malignancies

ConclusionsThe combination of vemurafenib, carboplatin, and paclitaxel is well tolerated and demonstrates encouraging activity, predominantly in patients with advanced melanoma andBRAFV600 mutations, regardless of prior treatment with BRAF and/or MEK inhibitors.

Source: Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Minny Bhatty, Shumei Kato, Sarina A. Piha ‐Paul, Aung Naing, Vivek Subbiah, Helen J. Huang, Daniel D. Karp, Apostolia M. Tsimberidou, Ralph G. Zinner, Wen‐Jen Hwu, Milind Javle, Sapna P. Patel, Mimi I. Hu, Gauri R. Varadhachary, Anthony Tags: Original Article Source Type: research